


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: BEN-SASSON=2B

In re Application of:	)	Conf. No.: 6540
	)	
Shmuel BEN-SASSON	)	Art Unit: 1646
	)	
Appln. No.: 09/736,076	)	Examiner:
	)	
Filed: December 13, 2000	)	Washington, D.C.
	)	
For: SHORT PEPTIDES WHICH	)	February 22, 2002
SELECTIVELY MODULATE THE	)	
ACTIVITY OF SERINE/	)	
THREONINE INASES	)	



INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above- identified application, and any other application relying on the filing date of the above-identified application or cross- referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

[ ] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

☒ B. before the mailing date of a first office action on the merits.

☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

*(Check one of the boxes "i" and "ii" below:)*

☐ i. Counsel certifies that, upon information and belief, each item of information listed herein was either

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

☐ ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$180.00.

☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR §1.97(d) for consideration of this IDS. *(use one and delete other of following and this note)* A check (check no. \_\_\_\_\_) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(i), presently believed to be \$130 is enclosed. Counsel certifies

that, upon information and belief, each item of information listed herein was either

*(Check one of the boxes "a" and "b" below)*

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

☒ 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

*(check boxes A and/or B and fill in blanks, if appropriate)*

☐ A. Document(s) \_\_\_\_\_ is (are) deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

☒ B. Documents AA-AW were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

08/861,338, filed May 21, 1997

Applicant(s) identifies these documents by attaching hereto a fresh PTO-1449 listing these documents, and request that they

be considered and made of record in accordance with \$1.98(d). Per 37 CFR \$1.98(d), copies of these documents need not be filed in this application.

☐ 3. Document(s) \_\_\_\_\_ is (are) not in the English language. In accordance with \$1.98(c), Applicant(s) states:

☐ An English translation of each document \_\_\_\_\_ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is found in the attached \_\_\_\_\_ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is set forth as follows:

*(insert concise explanation of relevance)*

☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.

☐ A concise explanation of document(s) \_\_\_\_\_ can be found on the attached sheet.

☒ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

☐ 5. Other information being provided for the examiner's consideration follows:


*(insert other information)*

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By:

  
Roger L. Browdy  
Reg. No. 20,520

624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528

Substitute for form 1449A/PTO		FEB 22 2002		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/736,076
				Filing Date	December 13, 2000
				First Named Inventor	Shmuel BEN-SASSON
				Group Art Unit	1646
				Examiner Name	
Sheet 1	of 2			Attorney Docket Number	BEN-SASSON=2B

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent Number	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	WO	93/16703	A1	Nambi et al	09-02-1993	
	AB	WO	97/14038	A1	Mochley-Rosen et al	04-17-1997	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published					
	AC	ALEMÁ et al, "Differentiation of PC12 pheochromocytoma cells induced by v-src oncogene", <u>Nature</u> 316(6028):557-559 (1985)					
	AD	BIRCHALL et al, "Ro 32-0432, a Selective and Orally Active Inhibitor of Protein Kinase C Prevents T-Cell Activation", <u>J Pharmacol Exp Ther</u> 268(2):922-929 (1994)					
	AE	BRADSHAW et al, "Therapeutic potential of protein kinase C inhibitors", <u>Agents Actions</u> 38(1-2):135-147 (1993)					
	AF	DUDEK et al, "Regulation of neuronal Survival by the Serine-Threonine Protein Kinase Akt", <u>Science</u> 275:661-665 (1997)					
	AG	FRANKE et al, "P13K: Downstream AKTion Blocks Apoptosis", <u>Cell</u> 88:435-437 (1997)					
	AH	FREEDMAN et al, "Desensitization of G Protein-Coupled Receptors", <u>Recent Prog Horm Res</u> 51:319-353 (1996)					
	AI	GHISO et al, "Binding of Cystatin C to C4: The Importance of Sense-Antisense Peptides in their Interaction", <u>Proc Nat Acad Sci USA</u> 87(4):1288-1294 (1990)					
	AJ	GLOVER et al, "Polo-Kinase: The Choreographer of the Mitotic Stage?", <u>J Cell Biol</u> 135:1681-1684 (1996)					
	AK	HANKS et al, "The Eukaryotic Protein Kinase Superfamily in <u>The Protein Kinase Facts Book</u> , Vol. 1, Hardie et al, eds., Academic Press, Chapter 2 (1995)					
	AL	HEMMINGS BA, "Akt Signaling: Linking Membrane Events to Life and Death Decisions", <u>Science</u> 275:628-631 (1997)					

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449 PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

**Complete if Known**

Application Number	09/736,076
Filing Date	December 13, 2000
First Named Inventor	Shmuel BEN-SASSON
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	BEN-SASSON=2B

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AM	HUBBARD et al, "Crystal structure of the tyrosine kinase domain of the human insulin receptor", <u>Nature</u> 372:746-753 (1994)	
	AN	KOHN et al, Expression of a Constitutively Active Akt Ser/Thr Kinase in 3T3-L1 Adipocytes Stimulates Glucose Uptake and Glucose Transporter 4 Translocation" <u>J Biol Chem</u> 271(49):31372-31378 (1996)	
	AO	LANGE-CARTER et al, "A Divergence in the MAP Kinase Regulatory Network defined by MEK Kinase and Raf", <u>Science</u> 260:315-318 (1993)	
	AP	LOVRIĆ et al, "Activation of Mit/Raf protein kinases in mitotic cells", <u>Oncogene</u> 12:1109-1116 (1996)	
	AQ	MASON IJ, "Th Ins and Outs of Fibroblast Growth Factors", <u>Cell</u> 78:547-552 (1994)	
	AR	McMURRAY et al, "Cyclic peptide substrates of pp60c-src: synthesis and evaluation", <u>Int J Pept Protein Res</u> 42(3):209-215 (1993) (from <u>Chem Abstracts</u> 1993, Acc. No. 120:100177)	
	AS	MOHAMMADI et al, "Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism", <u>Cell</u> 86:577-587 (1996)	
	AT	NISHIZUKA Y, "Protein kinase C and lipid signaling for sustained cellular responses", <u>FASEB J</u> 9:484-496 (1995)	
	AU	OKADA et al, "Synthesis of Gln-Val-Val-Ala-Gly, a common sequence of thiol proteinase inhibitors, and its derivatives. Relationship between structure and effect on thiol proteinases", <u>Pept Chem</u> 653-656 (1998) (from <u>Chem Abstracts</u> , 1998, Acc. No. 109:69322)	
	AV	SIMMONS et al, "Identification of an early-growth-response gene encoding a novel putative protein kinase", <u>Mol Cell Biol</u> 12(9):4164-4169 (1992)	
	AW	TAYLOR et al, "cAMP-dependent protein kinase defines a family of enzymes", <u>Phil Trans R Soc Lond B</u> 340:315-324 (1993)	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---

<b>Application Number</b>	09/736,076
<b>Filing Date</b>	December 13, 2000
<b>First Named Inventor</b>	Shmuel BEN-SASSON
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	BEN-SASSON=2B

[illegible]Date  
Considered

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.